Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931499 | 0.87 | HSPA5 (0.37) | HSPA5KEAP1IDO1ESRRACYP2D6 | |
| SCHEMBL28898995 | 0.81 | MPO (0.42) | HSPA5IDO1CYP2D6TSHRHIF1A | |
| SCHEMBL28758851 | 0.79 | IDO1 (0.44) | IDO1TSHRTAAR1CA12CA9 | |
| SCHEMBL12468870 | 0.79 | IDO1 (0.40) | IDO1TAAR1MPO | |
| SCHEMBL11294215 | 0.78 | ALDH1A1 (0.40) | CYP2D6TSHRHIF1ACYP1A2 | |
| SCHEMBL2825597 | 0.76 | DPP4 (0.43) | — | |
| SCHEMBL8913075 | 0.76 | KMT2A (0.40) | IDO1 | |
| SCHEMBL1851278 | 0.75 | GPR84 (0.62) | CYP2D6TSHRTAAR1CYP1A2MPO | |
| SCHEMBL4666774 | 0.75 | CYP19A1 (0.39) | — | |
| SCHEMBL29272 | 0.73 | ALDH1A1 (0.46) | CYP2D6TSHRTAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220079936-A1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS (US) | 2022-03-17 | — | — | US | disclosed |
| US-10463659-B2 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180021444-A1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS | 2018-01-25 | — | — | US | disclosed |
| US-9808533-B2 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS (US) | 2017-11-07 | — | — | US | disclosed |
| EP-1675622-B1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170056514-A1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS | 2017-03-02 | — | — | US | disclosed |
| US-9333200-B2 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140323514-A1 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS | 2014-10-30 | — | — | US | disclosed |
| US-8771662-B2 | Multi-arm polymer prodrugs | NEKTAR THERAPEUTICS (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2626083-A1 | Multi-arm polymer prodrugs | Nektar Therapeutics (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2005028539-A2 | MULTI-ARM POLYMER PRODRUGS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| CN-1433307-A | Prostaglandin compounds for treating congestive heart failure | UNITED THERAPEUTICS CORP (US) | 2003-07-30 | — | — | CN | disclosed |
| WO-2003049676-A2 | MODIFIED PROSTAGLANDIN COMPOUNDS AND ANALOGS THEREOF, COMPOSITIONS CONTAINING THE SAME USEFUL FOR THE TEATMENT OF CANCER | UNITED THERAPEUTICS CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030108512-A1 | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer | UNITED THERAPEUTICS CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1299096-A1 | PROSTAGLANDIN COMPOUNDS FOR TREATING CONGESTIVE HEART FAILURE | United Therapeutics Corporation (US) | 2003-04-09 | — | — | EP | disclosed |
| CN-1354622-A | Prostaglandin compound, compositions and methods of treating peripheral vascular disease and pulmonary hypertension | UNITED THERAPEUTICS CORP (US) | 2002-06-19 | — | — | CN | disclosed |
| EP-1164846-A1 | PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING PERIPHERAL VASCULAR DISEASE AND PULMONARY HYPERTENSION | United Therapeutics Corporation (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001093862-A1 | PROSTAGLANDIN COMPOUNDS FOR TREATING CONGESTIVE HEART FAILURE | UNITED THERAPEUTICS CORPORATION (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6242482-B1 | BONDED TO POLYMER | UNITED THERAPEUTICS CORPORATION | 2001-06-05 | — | — | US | disclosed |
| WO-2000057701-A1 | PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING PERIPHERAL VASCULAR DISEASE AND PULMONARY HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323514-A1 | MULTI-ARM POLYMER PRODRUGS | PAICS, CD38, ENTPD1 | HSPA5 2335/4885KEAP1 2594/4885IDO1 739/4885 |
| US-10463659-B2 | Multi-arm polymer prodrugs | PAICS, CD38, ENTPD1 | HSPA5 2335/4885KEAP1 2594/4885IDO1 739/4885 |
| US-20180021444-A1 | MULTI-ARM POLYMER PRODRUGS | PAICS, CD38, ENTPD1 | HSPA5 2335/4885KEAP1 2594/4885IDO1 739/4885 |
| US-20170056514-A1 | MULTI-ARM POLYMER PRODRUGS | PAICS, CD38, ENTPD1 | HSPA5 2335/4885KEAP1 2594/4885IDO1 739/4885 |
| US-20030108512-A1 | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer | PTGES, PTGER1, PTGIR | HSPA5 2404/4885KEAP1 866/4885IDO1 1517/4885 |
| US-20220079936-A1 | MULTI-ARM POLYMER PRODRUGS | PAICS, CD38, ENTPD1 | HSPA5 2335/4885KEAP1 2594/4885IDO1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.